Clearmind Medicine Inc. announced significant progress in its multinational Phase I/IIa clinical trial of CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound developed for the treatment of Alcohol Use Disorder (AUD). In 2025, the company completed site activations at leading institutions, including Yale School of Medicine and Johns Hopkins University School of Medicine, and successfully initiated first-in-human dosing. Enrollment and dosing for the first two cohorts have been completed, with positive top-line safety and tolerability results reported and no serious adverse events observed. The Data and Safety Monitoring Board (DSMB) provided unanimous approval to continue the study following an interim review. Additional clinical data readouts are expected as the trial progresses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9616979-en) on December 24, 2025, and is solely responsible for the information contained therein.